When you pick up your Wegovy, Ozempic or Mounjaro pen for the first time and read through the information leaflet, you may notice a prominent warning about the thyroid. For many people, this is the most alarming thing in the whole document — and it raises an understandable question: is this medication going to harm my thyroid?

The answer requires a bit of context. The warning is real, it is there for a reason, and there are a small number of people who genuinely should not use these medications. But for the vast majority of patients, the thyroid warning does not change the risk-benefit calculation. Here is a clear, honest overview of what we know.

What does the thyroid warning actually mean?

Both semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (Mounjaro) carry what regulators call a black box warning — the most prominent type of safety notice on a prescription drug label. The warning reads that these medications caused thyroid C-cell tumours in rodents during studies conducted at high doses over long periods.

C-cells are a small population of cells in the thyroid gland that produce calcitonin, a hormone involved in calcium regulation. In rats and mice exposed to GLP-1 receptor agonists at doses far higher than those used in humans, a dose- and duration-dependent increase in C-cell tumours was observed.

Critically, the relevance of these findings to humans is unknown. Human thyroid C-cells have far fewer GLP-1 receptors than rodent C-cells, which may explain why the animal effect has not been replicated in human studies. The warning is a precautionary measure required by regulators whenever this type of signal appears in animal toxicology — it does not mean the drug has been shown to cause thyroid cancer in people.

Who should not use GLP-1 medications because of thyroid risk?

There are two groups for whom these medications are contraindicated due to thyroid concerns:

It is important to note that these conditions are rare. The vast majority of people starting GLP-1 therapy are not affected. If you are unsure whether you have a relevant family history, ask your doctor before starting treatment.

For people with a history of papillary or follicular thyroid cancer (the most common types), GLP-1 medications are generally not contraindicated — these cancers originate in different thyroid cells (follicular cells, not C-cells). Always discuss your full medical history with your doctor.

What warning signs should you watch for?

Regardless of your history, all patients on GLP-1 medication should be alert to the following symptoms, which could indicate a thyroid problem:

If you notice any of these symptoms, contact your doctor promptly. In most cases there will be a completely unrelated explanation, but these symptoms should always be investigated when they arise during treatment.

Does your thyroid need to be monitored during treatment?

For the general population starting GLP-1 medication, routine thyroid cancer screening is not recommended. Medullary thyroid carcinoma is rare, and there is no established benefit to screening people who have no symptoms and no risk factors.

However, if you already have a pre-existing thyroid condition — particularly hypothyroidism (an underactive thyroid) — it is worth keeping a closer eye on your thyroid function. As you lose weight on GLP-1 medication, the doses of thyroid hormone replacement you need may change. This is not due to the medication itself affecting your thyroid, but because body weight influences how thyroid medications are distributed and metabolised. Your doctor may recommend periodic TSH (thyroid-stimulating hormone) blood tests to ensure your levels remain optimal.

What does the research actually show in humans?

Since GLP-1 medications were introduced, researchers have actively studied whether a real-world thyroid cancer signal exists in humans. The picture is reassuring for most people, though the research is ongoing.

A large observational study published in Diabetes Care (Bezin et al., 2023), which followed over 1.5 million patients, found a statistically significant increase in medullary thyroid cancer risk with long-term use of GLP-1 receptor agonists compared to other diabetes medications. However, the absolute risk remained very small — fewer than 1 additional case per 1,000 patients over a decade — and the study's authors noted limitations including the rarity of MTC and potential confounding factors.

Other large studies, including an analysis published in JAMA, have found no overall increase in thyroid cancer risk with semaglutide when compared to other anti-obesity or diabetes medications.

Regulators in both the US (FDA) and Europe (EMA) continue to monitor the situation. The current consensus is that the established benefits of GLP-1 therapy — significant weight loss and cardiovascular protection — outweigh the theoretical thyroid risk for the general population, while the contraindications for MTC/MEN2 remain firmly in place.

Do GLP-1 medications affect thyroid function more broadly?

Beyond the cancer question, some patients wonder whether GLP-1 medications affect the day-to-day function of the thyroid — hormone levels, metabolism, energy.

The short answer is: not directly in a clinically meaningful way for most people. GLP-1 receptors are present in thyroid tissue, and preclinical research has explored whether GLP-1 signalling plays a role in thyroid hormone regulation. Some small studies have observed minor changes in TSH or calcitonin levels in people taking GLP-1 receptor agonists, but these changes are generally within the normal range and not considered clinically significant.

What does change is your body weight — and weight loss can independently affect thyroid function and medication requirements. This is the more practically relevant connection for most patients already being treated for a thyroid condition.

What if you already have a thyroid condition?

Here is a quick summary for people with common thyroid conditions:

The bottom line

The thyroid warning on GLP-1 medications is based on animal studies and reflects a genuine regulatory precaution — not a confirmed human risk for most patients. For the overwhelming majority of people who use Wegovy, Ozempic or Mounjaro, the thyroid warning does not change the overall benefit-risk balance, which remains favourable.

If you have a personal or family history of medullary thyroid cancer or MEN2, speak to your doctor before starting — these medications may not be right for you. And regardless of your history, be aware of the neck and throat symptoms listed above, and report them promptly if they appear.

This article is for informational purposes only and does not constitute medical advice. Always consult your doctor or specialist about your individual treatment and any concerns about side effects.

Sources